Search Results

Physiologically Based Biopharmaceutics Modeling Coupled with Biopredictive Dissolution in Development of Bioequivalent Formulation for Mesalamine Enteric Coated Tablet: A Tough Nut to Crack.

• Authors : Kollipara S; Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Bachupally, Medchal Malkajgiri District, Hyderabad, 500090, Telangana, India. .; Prabhat PK

Subjects: Mesalamine*/Mesalamine*/Mesalamine*/pharmacokinetics ; Mesalamine*/Mesalamine*/Mesalamine*/administration & dosage ; Mesalamine*/Mesalamine*/Mesalamine*/chemistry

• Source: AAPS PharmSciTech [AAPS PharmSciTech] 2024 Dec 02; Vol. 26 (1), pp. 1. Date of Electronic Publication: 2024 Dec 02.Publisher: Springer Country of Publication: United States NLM ID: 100960111 Publication Model: Electronic Cited Medium: Internet ISSN: 1530-9932

Record details

A Semi-Mechanistic Physiologically Based Biopharmaceutics Model to Describe Complex and Saturable Absorption of Metformin: Justification of Dissolution Specifications for Extended Release Formulation.

• Authors : Bhattiprolu AK; Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), BachupallyMedchal Malkajgiri District, Hyderabad, Telangana, 500 090, India.; Kollipara S

Subjects: Metformin*/Metformin*/Metformin*/pharmacokinetics ; Metformin*/Metformin*/Metformin*/administration & dosage ; Metformin*/Metformin*/Metformin*/chemistry

• Source: AAPS PharmSciTech [AAPS PharmSciTech] 2024 Aug 21; Vol. 25 (7), pp. 193. Date of Electronic Publication: 2024 Aug 21.Publisher: Springer Country of Publication: United States NLM ID: 100960111 Publication Model: Electronic Cited Medium: Internet ISSN: 1530-9932

Record details

Development of in vitro biopharmaceutics tools for predicting the bioavailability of subcutaneously injected monoclonal antibodies and oligonucleotides.

• Authors : Somby K; King's College London, Institute of Pharmaceutical Science, London, England.; Novartis Pharma AG, Basel, Switzerland.

Subjects: Biological Availability* ; Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/administration & dosage ; Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/pharmacokinetics

• Source: Expert opinion on drug delivery [Expert Opin Drug Deliv] 2024 Sep; Vol. 21 (9), pp. 1307-1310. Date of Electronic Publication: 2024 Sep 21.Publisher: Informa Healthcare Country of Publication: England NLM ID: 101228421 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Lack of Effect of Antioxidants on Biopharmaceutics Classification System (BCS) Class III Drug Permeability.

• Authors : Chiang Yu Y; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, 21201, USA.; Lu D

Subjects: Antioxidants*/Antioxidants*/Antioxidants*/pharmacology ; Antioxidants*/Antioxidants*/Antioxidants*/pharmacokinetics ; Permeability*

• Source: Journal of pharmaceutical sciences [J Pharm Sci] 2024 Aug; Vol. 113 (8), pp. 2215-2222. Date of Electronic Publication: 2024 Mar 12.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Justification of widened dissolution specifications of an extended-release product using physiologically based biopharmaceutics modeling.

• Authors : Bhattiprolu AK; Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Telangana, India.; Kollipara S

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Delayed-Action Preparations* ; Therapeutic Equivalency*

• Source: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2024 Oct; Vol. 54 (10), pp. 781-795. Date of Electronic Publication: 2024 Oct 14.Publisher: Informa Healthcare Country of Publication: England NLM ID: 1306665 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report.

• Authors : Pepin X; Regulatory Affairs, Simulations Plus Inc., 42505 10th Street West, Lancaster, California 93534-7059, United States.; Arora S

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Models, Biological*; Humans

• Source: Molecular pharmaceutics [Mol Pharm] 2024 Aug 05; Vol. 21 (8), pp. 3697-3731. Date of Electronic Publication: 2024 Jun 30.Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.

• Authors : Mackie C; Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium.; Arora S

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Drug Industry*/Drug Industry*/Drug Industry*/methods; Humans

• Source: Molecular pharmaceutics [Mol Pharm] 2024 May 06; Vol. 21 (5), pp. 2065-2080. Date of Electronic Publication: 2024 Apr 10.Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Drug solubility in biorelevant media in the context of an inhalation-based biopharmaceutics classification system (iBCS).

• Authors : Floroiu A; Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany; Eurofins PHAST Development GmbH & Co. KG, 78467 Konstanz, Germany. Electronic address: .

Subjects: Biopharmaceutics* ; Intestines*; Pharmaceutical Preparations/Pharmaceutical Preparations/Pharmaceutical Preparations/chemistry

• Source: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 9109778 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives.

• Authors : Kollipara S; Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Bachupally, Medchal Malkajgiri District, Hyderabad, Telangana 500 090, India.; Martins FS

Subjects: Biopharmaceutics* ; Drugs, Generic*; Therapeutic Equivalency

• Source: Journal of pharmaceutical sciences [J Pharm Sci] 2024 Feb; Vol. 113 (2), pp. 345-358. Date of Electronic Publication: 2023 Dec 01.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Adult and pediatric physiologically-based biopharmaceutics modeling to explain lamotrigine immediate release absorption process.

• Authors : Caleffi-Marchesini ER; Pharmacokinetics and Biopharmaceutics Laboratory, State University of Maringá, Maringá, PR, Brazil.; Herling AA

Subjects: Biopharmaceutics* ; Intestinal Absorption*/Intestinal Absorption*/Intestinal Absorption*/physiology; Adult

• Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Feb; Vol. 13 (2), pp. 208-221. Date of Electronic Publication: 2023 Nov 14.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Using the refined Developability Classification System (rDCS) to guide the design of oral formulations.

• Authors : Beran K; Fraunhofer Institute for Translational Medicine and Pharmacology, Frankfurt am Main, Germany; Janssen Pharmaceutica NV, Pharmaceutical & Material Sciences, Beerse, Belgium.

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods; Administration, Oral ; Humans

• Source: Journal of pharmaceutical sciences [J Pharm Sci] 2024 Dec; Vol. 113 (12), pp. 3497-3517. Date of Electronic Publication: 2024 Oct 05.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Neural Network Models for Predicting Solubility and Metabolism Class of Drugs in the Biopharmaceutics Drug Disposition Classification System (BDDCS).

• Authors : Ashrafi A; Faculty of Electrical and Computer Engineering, University of Tabriz, Tabriz, Iran.; Teimouri K

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Neural Networks, Computer*; Solubility

• Source: European journal of drug metabolism and pharmacokinetics [Eur J Drug Metab Pharmacokinet] 2024 Jan; Vol. 49 (1), pp. 1-6. Date of Electronic Publication: 2023 Oct 21.Publisher: Springer France Country of Publication: France NLM ID: 7608491 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

iBCS: 3. A Biopharmaceutics Classification System for Orally Inhaled Drug Products.

• Authors : Hastedt JE; JDP Pharma Consulting, San Carlos, California 94070, United States.; Bäckman P

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Nebulizers and Vaporizers*; Solubility

• Source: Molecular pharmaceutics [Mol Pharm] 2024 Jan 01; Vol. 21 (1), pp. 164-172. Date of Electronic Publication: 2023 Dec 07.Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products.

• Authors : Jadhav H; Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca Gothenburg, S-431 83 Mölndal, Sweden.; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, ON2 Herestraat 49, 3000 Leuven, Belgium.

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Intestinal Absorption*/Intestinal Absorption*/Intestinal Absorption*/physiology; Humans

• Source: Molecular pharmaceutics [Mol Pharm] 2023 Dec 04; Vol. 20 (12), pp. 6272-6288. Date of Electronic Publication: 2023 Oct 30.Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Retrospective analysis of the biopharmaceutics characteristics of solid oral Modified-Release drug products in approved US FDA NDAs designated as Extended-Release or Delayed-Release formulations.

• Authors : Ahmed N; U.S. Food and Drug Administration (FDA), United States. Electronic address: .; Ly H

Subjects: Biopharmaceutics* ; Polymers*; United States

• Source: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 9109778 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

[Reform and exploration of biopharmaceutics blended teaching in the context of "first-class undergraduate education"].

• Authors : Cai W; School of Life Sciences, Hubei University, Wuhan 430062, Hubei, China.; Lei J

Subjects: Biopharmaceutics* ; Curriculum*; Humans

• Source: Sheng wu gong cheng xue bao = Chinese journal of biotechnology [Sheng Wu Gong Cheng Xue Bao] 2023 Dec 25; Vol. 39 (12), pp. 5014-5023.Publisher: Ke xue chu ban she Country of Publication: China NLM ID: 9426463 Publication Model: Print Cited Medium: Internet ISSN: 1872-2075

Record details

Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space.

• Authors : Miranda Dos Santos E; Department of Pharmaceutical Sciences, Institute of Environmental, Chemical and Pharmaceutical Sciences, Universidade Federal de São Paulo, UNIFESP, Rua São Nicolau, 210, Centro, Diadema, 09913-030, SP, Brazil.; Ferraz HG

Subjects: Biopharmaceutics* ; Models, Biological*; Therapeutic Equivalency

• Source: Journal of pharmaceutical sciences [J Pharm Sci] 2023 Dec; Vol. 112 (12), pp. 3131-3140. Date of Electronic Publication: 2023 Jul 19.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Revamping Biopharmaceutics-Pharmacokinetics with Scientific and Regulatory Implications for Oral Drug Absorption.

• Authors : Alimpertis N; Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.; PharmaInformatics Unit, ATHENA Research Center, Athens, Greece.

Subjects: Biopharmaceutics* ; Models, Biological*; Therapeutic Equivalency

• Source: Pharmaceutical research [Pharm Res] 2023 Sep; Vol. 40 (9), pp. 2167-2175. Date of Electronic Publication: 2023 Aug 03.Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Print-Electronic Cited Medium:

Record details

Biopharmaceutics : From Fundamentals to Industrial Practice

• Authors : Hannah Batchelor

Subjects: Biopharmaceutics--methods; Drug DesignMEDICAL / Pharmacology

Record details

SubQ-Sim: A Subcutaneous Physiologically Based Biopharmaceutics Model. Part 1: The Injection and System Parameters.

• Authors : Pepin XJH; Regulatory Affairs, Simulations Plus, Lancaster, CA, USA.; Grant I

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Diabetes Mellitus, Type 2*; Humans

• Source: Pharmaceutical research [Pharm Res] 2023 Sep; Vol. 40 (9), pp. 2195-2214. Date of Electronic Publication: 2023 Aug 27.Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Print-Electronic Cited Medium:

Record details

Biopharmaceutics Risk Assessment-Connecting Critical Bioavailability Attributes with In Vitro, In Vivo Properties and Physiologically Based Biopharmaceutics Modeling to Enable Generic Regulatory Submissions.

• Authors : Ahmed T; Biopharmaceutics Group, Global Clinical Management, Integrated Product Development Organization (IPDO), Dr. Reddy's Laboratories Ltd, Bachupally, Medchal Malkajgiri District, Hyderabad-500 090, Telangana, Hyderabad, India. .; Kollipara S

Subjects: Drugs, Generic*/Drugs, Generic*/Drugs, Generic*/adverse effects ; Drugs, Generic*/Drugs, Generic*/Drugs, Generic*/pharmacokinetics ; Therapeutic Equivalency*

• Source: The AAPS journal [AAPS J] 2023 Jul 27; Vol. 25 (5), pp. 77. Date of Electronic Publication: 2023 Jul 27.Publisher: American Association of Pharmaceutical Scientists Country of Publication: United States NLM ID: 101223209 Publication Model: Electronic Cited

Record details

Drug Permeability - Best Practices for Biopharmaceutics Classification System (BCS)-Based Biowaivers: A workshop Summary Report.

• Authors : Mehta M; US Food & Drug Administration, Silver Spring, MD, USA. Electronic address: .; Polli JE

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Research Report*; Pharmaceutical Preparations

• Source: Journal of pharmaceutical sciences [J Pharm Sci] 2023 Jul; Vol. 112 (7), pp. 1749-1762. Date of Electronic Publication: 2023 May 03.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Physiologically based biopharmaceutics modeling of regional and colon absorption in humans.

• Authors : Tannergren C; Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden. Electronic address: .; Jadhav H

Subjects: Biopharmaceutics* ; Intestinal Absorption*/Intestinal Absorption*/Intestinal Absorption*/physiology; Humans

• Source: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 9109778 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Combined Liquid-State and Solid-State Nuclear Magnetic Resonance at Natural Abundance for Comparative Higher Order Structure Assessment in the Formulated-State of Biphasic Biopharmaceutics.

• Authors : Pujahari SR; Department of Biosciences and Bioengineering, IIT Bombay, Powai, Mumbai 400076, India.; Mali PS

Subjects: Biopharmaceutics* ; Proteins*/Proteins*/Proteins*/chemistry; Magnetic Resonance Spectroscopy/Magnetic Resonance Spectroscopy/Magnetic Resonance Spectroscopy/methods

• Source: Analytical chemistry [Anal Chem] 2023 Jun 06; Vol. 95 (22), pp. 8469-8477. Date of Electronic Publication: 2023 May 08.Publisher: American Chemical Society Country of Publication: United States NLM ID: 0370536 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective.

• Authors : Kollipara S; Biopharmaceutics Group, Global Clinical Management, Integrated Product Development Organization (IPDO), Dr. Reddy's Laboratories Ltd, Bachupally, Medchal Malkajgiri District, Hyderabad, 500 090, Telangana, India.; Bhattiprolu AK

Subjects: Biopharmaceutics* ; Models, Biological*; Solubility

• Source: AAPS PharmSciTech [AAPS PharmSciTech] 2023 Feb 09; Vol. 24 (2), pp. 59. Date of Electronic Publication: 2023 Feb 09.Publisher: Springer Country of Publication: United States NLM ID: 100960111 Publication Model: Electronic Cited Medium: Internet ISSN: 1530-9932

Record details

Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs.

• Authors : Wu D; Pharmaceutical Sciences, MRL, Merck & Co., Inc., Rahway, New Jersey, 07065, USA.; Sanghavi M

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Drugs, Generic*; Therapeutic Equivalency

• Source: Pharmaceutical research [Pharm Res] 2023 Feb; Vol. 40 (2), pp. 337-357. Date of Electronic Publication: 2022 Jul 15.Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Print-Electronic Cited Medium:

Record details

Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development.

• Authors : Wu D; Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc., Rahway, NJ, 07065, USA.; Li M

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Drug Development*/Drug Development*/Drug Development*/methods; Humans

• Source: Pharmaceutical research [Pharm Res] 2023 Feb; Vol. 40 (2), pp. 321-336. Date of Electronic Publication: 2022 Sep 08.Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Print-Electronic Cited Medium:

Record details

Physiologically Based Biopharmaceutics Model for Selumetinib Food Effect Investigation and Capsule Dissolution Safe Space - Part I: Adults.

• Authors : Pepin XJH; New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK.; Hammarberg M

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Models, Biological*; Adult

• Source: Pharmaceutical research [Pharm Res] 2023 Feb; Vol. 40 (2), pp. 387-403. Date of Electronic Publication: 2022 Aug 24.Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Print-Electronic Cited Medium:

Record details

Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039.

• Authors : Kourentas A; Dissolution & Biopharmaceutics, Analytical Research and Development, Technical Research and Development, Novartis AG, CH-4056, Basel, Switzerland.; Gajewska M

Subjects: Biopharmaceutics* ; Models, Biological*; Adult

• Source: The AAPS journal [AAPS J] 2023 Feb 14; Vol. 25 (1), pp. 25. Date of Electronic Publication: 2023 Feb 14.Publisher: American Association of Pharmaceutical Scientists Country of Publication: United States NLM ID: 101223209 Publication Model: Electronic Cited

Record details

The pulmonary biopharmaceutics and anti-inflammatory effects after intratracheal and intravenous administration of Re-Du-Ning injection.

• Authors : Jia-Xing W; Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicines, Ministry of Education, Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences & Peking Union Medical College, No. 151 Malianwa North Road, Haidian District, Beijing 100193, PR China.; Chao-Yi L

Subjects: Biopharmaceutics* ; Medicine, Chinese Traditional*; Animals

• Source: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Apr; Vol. 160, pp. 114335. Date of Electronic Publication: 2023 Jan 30.Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 8213295 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Dissolution-Hollow Fiber Membrane (D-HFM) System to Anticipate Biopharmaceutics Risk of Tablets and Capsules.

• Authors : Adhikari A; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, 21201, USA.; Seo PR

Subjects: Biopharmaceutics*; Humans ; Solubility

• Source: Journal of pharmaceutical sciences [J Pharm Sci] 2023 Mar; Vol. 112 (3), pp. 751-759. Date of Electronic Publication: 2022 Oct 04.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Acalabrutinib Maleate Tablets: The Physiologically Based Biopharmaceutics Model behind the Drug Product Dissolution Specification.

• Authors : Pepin X; New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Charter Way, SK10 2NA Macclesfield, United Kingdom.; McAlpine V

Subjects: Biopharmaceutics* ; Models, Biological*; Humans

• Source: Molecular pharmaceutics [Mol Pharm] 2023 Apr 03; Vol. 20 (4), pp. 2181-2193. Date of Electronic Publication: 2023 Mar 01.Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Effect of the Tubing Material Used in Peristaltic Pumping in Tangential Flow Filtration Processes of Biopharmaceutics on Particle Formation and Flux.

• Authors : Deiringer N; Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universität München, Munich, Germany.; Leitner I

Subjects: Biopharmaceutics* ; Ultrafiltration*/Ultrafiltration*/Ultrafiltration*/methods; Filtration

• Source: Journal of pharmaceutical sciences [J Pharm Sci] 2023 Mar; Vol. 112 (3), pp. 665-672. Date of Electronic Publication: 2022 Oct 09.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Mechanistic Modeling of In Vitro Biopharmaceutic Data for a Weak Acid Drug: A Pathway Towards Deriving Fundamental Parameters for Physiologically Based Biopharmaceutic Modeling.

• Authors : Kowthavarapu VK; Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics Lake Nona (Orlando), College of Pharmacy, University of Florida, 6550 Sanger Road, Office 467, Orlando, Florida, 32827, USA.; Charbe NB

Subjects: Biopharmaceutics* ; Models, Biological*; Solubility

• Source: The AAPS journal [AAPS J] 2024 Apr 04; Vol. 26 (3), pp. 44. Date of Electronic Publication: 2024 Apr 04.Publisher: American Association of Pharmaceutical Scientists Country of Publication: United States NLM ID: 101223209 Publication Model: Electronic Cited

Record details

Utility of Physiologically Based Biopharmaceutics Modeling (PBBM) in Regulatory Perspective: Application to Supersede f2, Enabling Biowaivers & Creation of Dissolution Safe Space.

• Authors : Bhattiprolu AK; Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Bachupally, Medchal Malkajgiri District, Hyderabad-500 090, Telangana, India.; Kollipara S

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods; Solubility ; Therapeutic Equivalency

• Source: Journal of pharmaceutical sciences [J Pharm Sci] 2022 Dec; Vol. 111 (12), pp. 3397-3410. Date of Electronic Publication: 2022 Sep 09.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Modification of Tubings for Peristaltic Pumping of Biopharmaceutics.

• Authors : Deiringer N; Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University Munich, Munich, Germany.; Aleshkevich S

Subjects: Biopharmaceutics* ; Human Growth Hormone*; Humans

• Source: Journal of pharmaceutical sciences [J Pharm Sci] 2022 Dec; Vol. 111 (12), pp. 3251-3260. Date of Electronic Publication: 2022 Sep 02.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Using molecularly dissolved drug concentrations in PBBMs improves the prediction of oral absorption from supersaturating formulations.

• Authors : Holzem FL; Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark; Pharmaceutical R&D, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Colloids*; Humans

• Source: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2024 Mar 01; Vol. 194, pp. 106703. Date of Publisher: Elsevier Science B.V Country of Publication: Netherlands NLM ID: 9317982 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives.

• Authors : Anand O; Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, Maryland, USA. .; Pepin XJH

Subjects: Biopharmaceutics* ; Models, Biological*; Administration, Oral

• Source: Pharmaceutical research [Pharm Res] 2022 Aug; Vol. 39 (8), pp. 1681-1700. Date of Electronic Publication: 2022 May 18.Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Print-Electronic Cited Medium:

Record details

Current Applications of Multivariate Curve Resolution-Alternating Least Squares (MCR-ALS) in Pharmaceutical Analysis: Review.

• Authors : Alaoui Mansouri M; Nano and Molecular Systems Research Unit, University of Oulu, FI-90014 Oulu, Finland; University of Liege (ULiege), CIRM, Vibra-Santé HUB, Laboratory of Pharmaceutical Analytical Chemistry, CHU, B36, B-4000, Liege, Belgium. Electronic address: .

Subjects: Biopharmaceutics*; Least-Squares Analysis ; Pharmaceutical Preparations

• Source: Journal of pharmaceutical sciences [J Pharm Sci] 2024 Apr; Vol. 113 (4), pp. 856-865. Date of Electronic Publication: 2023 Dec 08.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Voices in Molecular Pharmaceutics : Meet Professor Owen S. Fenton, Designer of Lipid Nanoparticles for Messenger RNA Delivery.

• Authors : Fenton OS; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Subjects: Biopharmaceutics* ; Nanoparticles*; RNA, Messenger/RNA, Messenger/RNA, Messenger/genetics

• Source: Molecular pharmaceutics [Mol Pharm] 2024 Apr 01; Vol. 21 (4), pp. 1551-1552. Date of Electronic Publication: 2024 Mar 25.Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet

Record details

The role of artificial intelligence in generating original scientific research.

• Authors : Elbadawi M; UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK. Electronic address: .; Li H

Subjects: Artificial Intelligence* ; Biopharmaceutics*; Humans

• Source: International journal of pharmaceutics [Int J Pharm] 2024 Mar 05; Vol. 652, pp. 123741. Date of Electronic Publication: 2024 Jan 03.Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium:

Record details

Coupling Drug Dissolution with BCS.

• Authors : Simitopoulos A; Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.; Tsekouras A

Subjects: Biopharmaceutics*; Drug Liberation ; Permeability

• Source: Pharmaceutical research [Pharm Res] 2024 Mar; Vol. 41 (3), pp. 481-491. Date of Electronic Publication: 2024 Jan 30.Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Print-Electronic Cited Medium:

Record details

Biopharmaceutics studies applied to goyazensolide: a drug candidate from Lychnophora species.

• Authors : Tana IDT; Programa de Pós-graduação em Ciências Farmacêuticas, Escola de Farmácia, Universidade Federal de Ouro Preto, Campus Universitário Morro do Cruzeiro, Ouro Preto, Minas Gerais, Brazil.; Saúde-Guimarães DA

Subjects: Asteraceae*/Asteraceae*/Asteraceae*/chemistry ; Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods; Bridged-Ring Compounds

• Source: The Journal of pharmacy and pharmacology [J Pharm Pharmacol] 2022 Aug 19; Vol. 74 (8), pp. 1140-1151.Publisher: Oxford University Press Country of Publication: England NLM ID: 0376363 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Comparison study of physicochemical and biopharmaceutics properties of hydrophobic drugs ground by two dry milling processes.

• Authors : Dandignac M; Université de Toulouse, IMT Mines Albi, UMR CNRS 5302, Centre RAPSODEE, Albi Cedex, France.; Lacerda SP

Subjects: Biological Products* ; Biopharmaceutics*; Indomethacin/Indomethacin/Indomethacin/chemistry

• Source: Pharmaceutical development and technology [Pharm Dev Technol] 2022 Sep; Vol. 27 (7), pp. 816-828. Date of Electronic Publication: 2022 Sep 12.Publisher: Informa Healthcare Country of Publication: England NLM ID: 9610932 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

An Enabling Formulation of a Weakly Basic Compound Guided by Physiologically Based Biopharmaceutics Modeling (PBBM).

• Authors : Ibrahim F; Sanofi, Early Development Synthetics Platform, 153 Second Ave, Waltham, MA 02451, United States. Electronic address: .

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Excipients*; Administration, Oral

• Source: Journal of pharmaceutical sciences [J Pharm Sci] 2022 Sep; Vol. 111 (9), pp. 2490-2495. Date of Electronic Publication: 2022 Apr 16.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Dissolution of a Biopharmaceutics Classification System Class II Free Acid from Immediate Release Tablets Containing a Microenvironmental pH Modulator: Comparison of a Biorelevant Bicarbonate Buffering System with Phosphate Buffers.

• Authors : Haznar-Garbacz D; Department of Drug Form Technology, Wroclaw Medical University, 211a Borowska St., 50-556, Wrocław, Poland.; Hoc D

Subjects: Bicarbonates* ; Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods; Buffers

• Source: AAPS PharmSciTech [AAPS PharmSciTech] 2022 Jul 26; Vol. 23 (6), pp. 203. Date of Electronic Publication: 2022 Jul 26.Publisher: Springer Country of Publication: United States NLM ID: 100960111 Publication Model: Electronic Cited Medium: Internet ISSN: 1530-9932

Record details

iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System.

• Authors : Hastedt JE; JDP Pharma Consulting, San Carlos, California 94070, United States.; Bäckman P

Subjects: Biopharmaceutics*; Administration, Inhalation ; Administration, Oral

• Source: Molecular pharmaceutics [Mol Pharm] 2022 Jul 04; Vol. 19 (7), pp. 2032-2039. Date of Electronic Publication: 2022 May 16.Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Physiological based pharmacokinetic and biopharmaceutics modelling of subcutaneously administered compounds - An overview of in silico models.

• Authors : Dubbelboer IR; The Swedish Drug Delivery Center, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.; Sjögren E

Subjects: Biological Products* ; Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods; Computer Simulation

• Source: International journal of pharmaceutics [Int J Pharm] 2022 Jun 10; Vol. 621, pp. 121808. Date of Electronic Publication: 2022 May 06.Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium:

Record details

A Novel Approach to Justify Dissolution Differences in an Extended Release Drug Product using Physiologically Based Biopharmaceutics Modeling and Simulation.

• Authors : Aishwarya R; Biopharmaceutics - Global Clinical Management, Dr. Reddy's Laboratories Ltd, Hyderabad. Electronic address: .; Murthy A

Subjects: Biopharmaceutics* ; Models, Biological*; Administration, Oral

• Source: Journal of pharmaceutical sciences [J Pharm Sci] 2022 Jun; Vol. 111 (6), pp. 1820-1832. Date of Electronic Publication: 2022 Feb 23.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats.

• Authors : Khare S; Division of Microbiology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, USA.; Jog R

Subjects: Biopharmaceutics*/Biopharmaceutics*/Biopharmaceutics*/methods ; Nanoparticles*/Nanoparticles*/Nanoparticles*/toxicity; Hydroxyurea/Hydroxyurea/Hydroxyurea/*analogs & derivatives

• Source: Nanotoxicology [Nanotoxicology] 2023 Dec; Vol. 17 (10), pp. 583-603. Date of Electronic Publication: 2024 Jan 18.Publisher: Informa Healthcare Country of Publication: England NLM ID: 101233132 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details